Home › Chronische lymfatische leukemie › Missouri › Kansas City
Chronische lymfatische leukemie klinische studies in Kansas City, MO
10 studies voor Chronische lymfatische leukemie zoeken deelnemers op locaties in en rond Kansas City (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
RekruterenFase 3
- MidAmerica Cancer Care, LLC ( Site 5426), Kansas City
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
RekruterenFase 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- en nog 1
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Kansas City Veterans Affairs Medical Center, Kansas City
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RekruterenFase 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- Kansas City Veterans Affairs Medical Center, Kansas City
- en nog 2
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
RekruterenFase 1/2
- The University of Kansas Cancer Center, Westwood · 5 mijl verwijderd
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RekruterenFase 3
- The University of Kansas Cancer Center, Westwood · 5 mijl verwijderd
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
RekruterenFase 3
- MidAmerica Cancer Care, LLC ( Site 0043), Kansas City
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
RekruterenFase 3
- Saint Lukes Hospital of Kansas City /ID# 267270, Kansas City
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RekruterenFase 1/2
- University of Kansas, Westwood · 5 mijl verwijderd
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
RekruterenFase 2
- Kansas City VA Medical Center, Kansas City, MO, Kansas City
Chronische lymfatische leukemie studies in andere steden
- Boston, MA31 studies
- Columbus, OH28 studies
- Durham, NC27 studies
- Washington, DC22 studies
- Seattle, WA20 studies
- Rochester, MN18 studies
- New York City, NY18 studies
- Houston, TX17 studies
- Baldwin Park, CA16 studies
- Milwaukee, WI15 studies
- Chicago, IL14 studies
- Cincinnati, OH14 studies
Andere studies in Kansas City
- Borstkanker34 studies
- Niet-kleincellige longkanker31 studies
- Hartfalen25 studies
- Kanker (alle vormen)21 studies
- Longkanker19 studies
- Colorectale kanker16 studies
- Metastatische kanker15 studies
- Acute myeloïde leukemie15 studies
- Prostaatkanker14 studies
- Eierstokkanker11 studies
- Obesitas11 studies
- Type 2-diabetes11 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.